NICE recommends controlled use of targeted breast cancer radiotherapy treatment alongside further research

NICE has recommended the Intrabeam Radiotherapy System for people with early breast cancer in limited circumstances with additional data collection. The recommendation for further data to be collected is because it is not yet certain whether Intrabeam, marketed by Carl Zeiss UK, is as effective as conventional radiotherapy in stopping the cancer coming back.
NICE